Providers must review all concurrent medications, as GLP-1 agonists can potentiate the effect of other glucose-lowering agents, requiring insulin or sulfonylurea dose reductions during transition
An obesity medicine specialist is a valuable pregnancy care team member
Because of this complexity, supplement quality, dosing, and formulation matter far more than they do for basic nutritional support
Some GLP-1 agonists, like semaglutide and liraglutide, are also approved by the Food and Drug Administration (FDA) for treating obesity
Action Steps: Discuss with your healthcare provider about using semaglutide for diabetes or weight loss management
Discontinue use and contact your healthcare practitioner if you experience adverse reactions